The prevalence and outcome of short-acting β2-agonists overuse in asthma patients in Taiwan

被引：14
|
作者：
Wang, Cheng-Yi [1 ,2 ]
Lai, Chih-Cheng [3 ]
Wang, Ya-Hui [2 ,4 ]
Wang, Hao-Chien [5 ,6 ]
机构：
[1] Fu Jen Catholic Univ, Dept Internal Med, Cardinal Tien Hosp, New Taipei, Taiwan
[2] Fu Jen Catholic Univ, Coll Med, Sch Med, New Taipei, Taiwan
[3] Kaohsiung Vet Gen Hosp, Tainan Branch, Dept Internal Med, Tainan, Taiwan
[4] Fu Jen Catholic Univ, Med Res Ctr, Cardinal Tien Hosp, New Taipei, Taiwan
[5] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan
[6] Natl Taiwan Univ, Coll Med, Taipei, Taiwan
来源：
NPJ PRIMARY CARE RESPIRATORY MEDICINE | 2021年 / 31卷 / 01期
关键词：
INHALED CORTICOSTEROIDS; PREVENTION;
D O I：
10.1038/s41533-021-00231-1
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
This study aims to investigate the prevalence of short-acting beta 2-agonist (SABA) overuse in asthma and the associated risk of acute exacerbation and mortality in Taiwan. We used the Taiwanese pay-for-performance asthma program database, which included patients aged between 12 and 100 years who were enrolled in the program between 2001 and 2015. Among a total of 218,039 patients, 34,641 (15.9%) patients are classified as SABA over-users. Compared with patients who did not receive inhaled corticosteroids (ICS) and collected <= 2 canisters, SABA over-users had a higher risk of severe exacerbations. SABA over-users had a higher risk of all-cause mortality compared with patients who did not receive ICS and collected <= 2 canisters. The overall prevalence of SABA overuse in Taiwan is 15.9%, and this is even higher in concomitant ICS users. In addition, the overuse of SABA is associated with an increased risk of severe exacerbation and death.
引用
收藏
页数：7
相关论文
共 50 条
  • [1] The prevalence and outcome of short-acting β2-agonists overuse in asthma patients in Taiwan
    Cheng-Yi Wang
    Chih-Cheng Lai
    Ya-Hui Wang
    Hao-Chien Wang
    [J]. npj Primary Care Respiratory Medicine, 31
  • [2] Short-acting β2-agonists (SABA) overuse in asthma and patients' perceptions for this behavior
    Visser, Claire D.
    Faay, Maaike R. A.
    Ozdemir, Ayse
    Guchelaar, Henk-Jan
    Teichert, Martina
    [J]. RESPIRATORY MEDICINE, 2024, 231
  • [3] β2-agonists -: Short-acting β2-agonists
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 1999, 161 (11) : S28 - S31
  • [4] Paradoxical asthma hazard of short-acting β2-agonists
    Seed, M. J.
    Agius, R. M.
    [J]. ALLERGY, 2008, 63 (02) : 241 - 241
  • [5] Short-acting β2-agonists
    Lee, T
    Dennis, S
    [J]. LANCET, 2000, 356 (9233): : 940 - 941
  • [6] Identifying the drivers of patients' reliance on short-acting β2-agonists in asthma
    Blakeston, Sarah
    Harper, Gavin
    Zabala Mancebo, Julen
    [J]. JOURNAL OF ASTHMA, 2021, 58 (08) : 1094 - 1101
  • [7] The impact of the overuse of short-acting β2-agonists on the risk of sepsis and septic shock
    Lai, Chih-Cheng
    Chen, Chao-Hsien
    Wang, Ya-Hui
    Wang, Cheng-Yi
    Wang, Hao-Chien
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 150 (01) : 75 - +
  • [8] Dental caries in children with asthma undergoing treatment with short-acting β2-agonists
    Mazzoleni, S.
    Stellini, E.
    Cavaleri, E.
    Volponi, A. Angelova
    Ferro, R.
    Colombani, S. Fochesato
    [J]. EUROPEAN JOURNAL OF PAEDIATRIC DENTISTRY, 2008, 9 (03) : 132 - 138
  • [9] Short-acting β2-agonists and exacerbations in children with asthma in England: SABINA Junior
    Morgan, Ann
    Maslova, Ekaterina
    Kallis, Constantinos
    Sinha, Ian
    Roberts, Graham
    Tran, Trung N.
    van der Valk, Ralf J. P.
    Quint, Jennifer K.
    [J]. ERJ OPEN RESEARCH, 2023, 9 (02)
  • [10] Prevalence of overuse of short-acting beta-2 agonists (SABA) and associated factors among patients with asthma in Germany
    Worth, Heinrich
    Criee, Carl-Peter
    Vogelmeier, Claus F.
    Kardos, Peter
    Becker, Eva-Maria
    Kostev, Karel
    Mokros, Ingo
    Schneider, Andrea
    [J]. RESPIRATORY RESEARCH, 2021, 22 (01)
12345